1. Pink Sheet
  2. >>Geography
  3. >>Asia

Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting

 
• By Cole Werble

FDA has essentially shut down Ranbaxy’s three-year-old facility at Mohali as a source for products for the US market. But Ranbaxy is not alone among Indian firms in its quality product disputes with the agency. There is a significant uptick in activity by FDA in the region in what appears to be a period of intense culturization for the Indian firms into the ways FDA enforces cGMPs and handles on-site inspections.

Ranbaxy Laboratories Ltd. may be getting most of the headlines, but a large portion of the Indian pharmaceutical sector is getting close attention from the Food & Drug Administration, now emboldened and energized with new inspection tools from the FDA Safety & Innovation Act.

Using Warning Letters as a marker for the focus of inspection activity and the locus of problems found, India clearly moved to the top of FDA’s priority list for

More from India

More from Asia